Ad
related to: tiotropium respimat patient instructions- Patient Support
Find Savings, Samples & Resources.
Get Support For Your Patients.
- Safety Information
Explore Safety & Side Effects Info.
Compare STIOLTO® RESPIMAT® Here.
- Nebulized Medicine
Discover The Inhaleability.
Soft Mist Of STIOLTO® RESPIMAT®.
- Real-World Evidence
Compare STIOLTO® RESPIMAT®.
Get a Real-World Analysis Today.
- Patient Support
Search results
Results from the WOW.Com Content Network
Tiotropium is a muscarinic receptor antagonist, often referred to as an antimuscarinic or anticholinergic agent. Although it does not display selectivity for specific muscarinic receptors, when topically applied it acts mainly on M 3 muscarinic receptors [ 29 ] located on smooth muscle cells and submucosal glands.
Respimat, also known as Respimat Soft Mist Inhaler, is a drug delivery device used for the treatment of asthma, chronic obstructive pulmonary disease (COPD), and other respiratory conditions. Its developer, Boehringer Ingelheim , is currently [ when? ] conducting approved in the U.S. with a variety of their products, such as tiotropium and ...
olodaterol: approved in some European countries and Russia, and by the U.S. Food and Drug Administration (FDA) on July 31, 2014, under Striverdi Respimat [13] vilanterol is the ultra-LABA not available by itself but only as a component of combination drugs: with fluticasone furoate: Breo Ellipta , Relvar Ellipta (EU, RU).
Ipratropium bromide/salbutamol, sold under the brand name Combivent among others, is a combination medication used to treat chronic obstructive pulmonary disease (COPD). [1] [4] [5] It contains ipratropium (an anticholinergic) and salbutamol (albuterol, a β 2-adrenergic agonist).
Olodaterol (trade name Striverdi Respimat) is an ultra-long-acting β adrenoreceptor agonist (ultra-LABA) used as an inhalation for treating people with chronic obstructive pulmonary disease (COPD). It is manufactured by Boehringer Ingelheim .
On 18 November 2005, the U.S. Food and Drug Administration (FDA) alerted healthcare professionals and patients that several long-acting bronchodilator medicines have been associated with possible increased risk of worsening wheezing in some people, and requested that manufacturers update warnings in their existing product labeling.
The main contraindication for ipratropium in any form is hypersensitivity to atropine and related substances. [20] [21]Conditions such as narrow-angle glaucoma, prostatic hyperplasia, or bladder neck obstruction are not necessarily contraindicators, but should be taken into account, particularly if the patient is receiving an anticholinergic by another route.
Commonly prescribed drugs are prescribed according to guidelines around the world. For instance, for ischemic heart disease, the American College of Cardiology/American Heart Association (ACC/AHA) guideline is used in the United States and the European Society of Cardiology (ESC) guideline is used in Europe.
Ad
related to: tiotropium respimat patient instructions